Literature DB >> 26403473

Deferasirox-induced serious adverse reaction in a pediatric patient: pharmacokinetic and pharmacogenetic analysis.

M Marano1, G Bottaro2, B Goffredo3, F Stoppa4, M Pisani5, A M Marinaro6, F Deodato7, C Dionisi-Vici7, E Clementi8,9, F S Falvella10.   

Abstract

Entities:  

Keywords:  Adverse events; Deferasirox; Hyperammonemia; Hyperchloremic metabolic acidosis

Mesh：

Substances：

Year:  2015        PMID： 26403473     DOI： 10.1007/s00228-015-1956-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  10 in total

1.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin.

Authors:  Ji-Youn Han; Hyeong-Seok Lim; Eun Soon Shin; Yeon-Kyeong Yoo; Yong Hoon Park; Jong-Eun Lee; In-Jin Jang; Dae Ho Lee; Jin Soo Lee
Journal:  J Clin Oncol       Date:  2006-04-24       Impact factor: 44.544

Review 2.  Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications.

Authors:  Aki Sakurai; Ai Tamura; Yuko Onishi; Toshihisa Ishikawa
Journal:  Expert Opin Pharmacother       Date:  2005-11       Impact factor: 3.889

3.  Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience.

Authors:  Ali Aycicek; Ahmet Koc; Mahmut Abuhandan
Journal:  Pediatr Int       Date:  2014-05-30       Impact factor: 1.524

4.  Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.

Authors:  Taroh Satoh; Takashi Ura; Yasuhide Yamada; Kentaro Yamazaki; Toshimasa Tsujinaka; Masaki Munakata; Tomohiro Nishina; Shu Okamura; Taito Esaki; Yasutsuna Sasaki; Wasaburo Koizumi; Yoshihiro Kakeji; Naoki Ishizuka; Ichinosuke Hyodo; Yuh Sakata
Journal:  Cancer Sci       Date:  2011-08-12       Impact factor: 6.716

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.

Authors:  M Domenica Cappellini; Mohamed Bejaoui; Leyla Agaoglu; Duran Canatan; Marcello Capra; Alan Cohen; Guillermo Drelichman; Marina Economou; Slaheddine Fattoum; Antonis Kattamis; Yurdanur Kilinc; Silverio Perrotta; Antonio Piga; John B Porter; Louis Griffel; Victor Dong; Joan Clark; Yesim Aydinok
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

Review 7.  Renal tubular acidosis.

Authors:  J Rodríguez-Soriano; A Vallo
Journal:  Pediatr Nephrol       Date:  1990-05       Impact factor: 3.714

Review 8.  Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review.

Authors:  J C Stingl; H Bartels; R Viviani; M L Lehmann; J Brockmöller
Journal:  Pharmacol Ther       Date:  2013-09-27       Impact factor: 12.310

9.  Hyperchloremic metabolic acidosis due to deferasirox in a patient with beta thalassemia major.

Authors:  Nikolaos Papadopoulos; Aresti Vasiliki; Georgios Aloizos; Petros Tapinis; Athanasios Kikilas
Journal:  Ann Pharmacother       Date:  2009-11-24       Impact factor: 3.154

10.  Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.

Authors:  Gerard J M Bruin; Thomas Faller; Hansjörg Wiegand; Alain Schweitzer; Hanspeter Nick; Josef Schneider; K-Olaf Boernsen; Felix Waldmeier
Journal:  Drug Metab Dispos       Date:  2008-09-05       Impact factor: 3.922
  10 in total
  6 in total

1.  Significant Hyperbilirubinemia and Acute Hepatocellular Jaundice in a Pediatric Patient Receiving Deferasirox: A Case Report.

Authors:  Elizabeth A Feldman; Christopher D Miller; Sarabeth Wojnowicz; Robert Seabury
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Jan-Feb

2.  Joining the dots: Answers.

Authors:  Niladri Bose; Kaustabh Chaudhuri; Mordi Muorah; Rajiv Sinha
Journal:  Pediatr Nephrol       Date:  2022-01-27       Impact factor: 3.714

Review 3.  The Cross-Link between Ferroptosis and Kidney Diseases.

Authors:  Jingyu Wang; Yi Liu; Yaqing Wang; Li Sun
Journal:  Oxid Med Cell Longev       Date:  2021-05-03       Impact factor: 6.543

4.  What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis.

Authors:  Carmen Fucile; Francesca Mattioli; Valeria Marini; Massimo Gregori; Aurelio Sonzogni; Antonietta Martelli; Natalia Maximova
Journal:  Ther Clin Risk Manag       Date:  2018-09-07       Impact factor: 2.423

5.  Synthesis and Study of Multifunctional Cyclodextrin-Deferasirox Hybrids.

Authors:  Jose Miguel Gascon; Valentina Oliveri; Andrew McGown; Ecem Kaya; Yu-Lin Chen; Carol Austin; Martin Walker; Frances M Platt; Graziella Vecchio; John Spencer
Journal:  ChemMedChem       Date:  2019-06-24       Impact factor: 3.466

Review 6.  Kidney Tubular Damage Secondary to Deferasirox: Systematic Literature Review.

Authors:  Martin Scoglio; Maria Domenica Cappellini; Emanuela D'Angelo; Mario G Bianchetti; Sebastiano A G Lava; Carlo Agostoni; Gregorio P Milani
Journal:  Children (Basel)       Date:  2021-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.